Literature DB >> 8471655

Biology and treatment of myelodysplastic syndromes--developments in the past decade.

R Willemze1, W E Fibbe, J H Falkenburg, J C Kluin-Nelemans, P M Kluin, J E Landegent.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8471655     DOI： 10.1007/bf01697618

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  74 in total

1.  Recombinant human erythropoietin in patients with myelodysplastic syndromes.

Authors:  H C Schouten; E Vellenga; D J van Rhenen; J T de Wolf; P J Coppens; G H Blijham
Journal:  Leukemia       Date:  1991-05       Impact factor: 11.528

2.  Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors.

Authors:  G Verhoef; H Van den Berghe; M Boogaerts
Journal:  Leukemia       Date:  1992-08       Impact factor: 11.528

3.  The 5a-chromosome abnormality in haematological disorders: a collaborative study of 34 cases from the Netherlands.

Authors:  H Kerkhofs; A Hagemeijer; C H Leeksma; J Abels; G J den Ottolander; R Somers; W B Gerrits; M M Langenhuiÿen; A E von dem Borne; J O Van Hemel; J P Geraedts
Journal:  Br J Haematol       Date:  1982-11       Impact factor: 6.998

4.  Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.

Authors:  A Nagler; C Binet; M L Mackichan; R Negrin; C Bangs; T Donlon; P Greenberg
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

5.  In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemia.

Authors:  R Raymakers; T De Witte; J Joziasse; N Van der Lely; J Boezeman; C Haanen
Journal:  Br J Haematol       Date:  1991-05       Impact factor: 6.998

6.  Phase I study of recombinant human interleukin-3 in patients with bone marrow failure.

Authors:  R Kurzrock; M Talpaz; Z Estrov; M G Rosenblum; J U Gutterman
Journal:  J Clin Oncol       Date:  1991-07       Impact factor: 44.544

7.  Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.

Authors:  J W Janssen; M Buschle; M Layton; H G Drexler; J Lyons; H van den Berghe; H Heimpel; B Kubanek; E Kleihauer; G J Mufti
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

8.  Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.

Authors:  H P Koeffler; D Heitjan; R Mertelsmann; J E Kolitz; P Schulman; L Itri; P Gunter; E Besa
Journal:  Blood       Date:  1988-03       Impact factor: 22.113

Review 9.  Chromosomal deletions in the myelodysplastic syndrome.

Authors:  G J Mufti
Journal:  Leuk Res       Date:  1992       Impact factor: 3.156

10.  Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes.

Authors:  A Ganser; G Seipelt; A Lindemann; O G Ottmann; S Falk; M Eder; F Herrmann; R Becher; K Höffken; T Büchner
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113
View more
  3 in total

1.  Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes.

Authors:  Michael G Alexandrakis; Freda H Passam; Despina S Kyriakou; Constantina Dambaki; George Katrinakis; George Tsirakis; John Konsolas; Efstathios N Stathopoulos
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

2.  Bone marrow lymphocyte subsets in myelodysplastic syndromes.

Authors:  W Hilbe; W Eisterer; C Schmid; I Starz; H Silly; C Duba; C Ludescher; J Thaler
Journal:  J Clin Pathol       Date:  1994-06       Impact factor: 3.411

3.  Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome.

Authors:  C Bincoletto; S T Saad; E Soares da Silva; M L Queiroz
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.